Abstracts tagged "Behcet’s syndrome and thrombosis"

Abstract Number: 1808 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis
Aycan Gokturk¹, Sinem Nihal Esatoglu¹, Yesim Ozguler¹, Ersan Atahan², Benan Musellim², Vedat Hamuryudan¹, Hasan Yazici³ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey, ³Istanbul Academic Hospital, Istanbul, Turkey
Background/Purpose: Superior vena cava syndrome (SVCS), is a medical emergency and can also be seen in Behçet’s syndrome (BS). Contrary to the severe outcome seen…
Abstract Number: 2974 • 2016 ACR/ARHP Annual Meeting
An Outcome Survey of 100 Patients with Cerebral Venous Sinus Thrombosis Due to Behcet’s Syndrome Followed up at a Single, Dedicated Center
Enes Ali Kurt¹, Naci Kocer², Yesim Ozguler¹, Didar Ucar³, Ugur Uygunoglu⁴, Civan Islak⁵, Sebahattin Saip⁴, Melike Melikoglu¹, Vedat Hamuryudan¹, Yilmaz Ozyazgan³, Sebahattin Yurdakul¹, Aksel Siva⁴, Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Neuroradiology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neuroradiology, Istanbul, Turkey, ³Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Department of Neurology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey, ⁵Department of Neuroradiology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
Background/Purpose: Methods: We identified 100 (81 M/19 F) patients with BS who were diagnosed as having CVST. All contacted were called back to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].